Dechra is pleased to announce that it has received approval from the US Food and Drug Administration (FDA) for a generic antibiotic.
The product is expected to be a first generic market entrant in a substantial antibiotic market; it is the first registration Dechra has achieved through Putney’s development pipeline since it acquired the US-based business and clearly demonstrates the capabilities of our specialist pharma team, a key resource to the group.
Commenting on the approval, Dechra’s Chief Executive Officer, Ian Page, said: “We are delighted to receive this approval, which provides excellent growth opportunity for our US team and underpins our confidence in the strength of the recently acquired Putney business whilst further enhancing Dechra’s position in the US market.”
The group’s preliminary results for the year ended 30 June 2016 were released on 5 September 2016. The Annual Report is now available on the group website.